天津哈娜好醫材有限公司成立于1986年，是中國較早生產一次性使用醫用高分子制品的中外合資企業之一。公司于2020年4月進行了新一輪股權變更，現由天津天時澤投資管理中心全資控股。現公司總占地面積143677.63平方米。
多年來對品質的堅持為企業積累了良好的口碑，使企業保持著良好的市場占有率和競爭實力。目前，是天津醫療器械行業協會會員、天津國際交流協會會員、輸液器標委會委員、高分子行業協會會員、天津生物醫學工程學會成員，國家高新技術企業、天津市科技小巨人領軍培育企業。
以“HANACO”、“哈娜好”品牌生產的一次性使用輸液器、注射器、輸血器、頭皮針、血液透析管路、動靜脈穿刺針、造影導管、采血針等系列產品，均達到國際標準，通過了ISO13485和CE認證。在醫療器械GMP推行初期，作為試點企業首批通過認證，同時，公司歷經多次美國FDA工廠審核并通過。產品覆蓋全中國并遠銷南北美洲、歐洲、亞洲等，在國內有天津、北京、上海、沈陽、哈爾濱、武漢、西安、杭州、南京等十余個辦事處及數十家分銷商，產品外銷美國、日本、韓國、沙特阿拉伯、菲律賓、斯里蘭卡以及南非地區國家等近20個國家。
企業目前占地面積58794平方米，其中天逸工廠40010.3平方米，建筑面積10227.57平方米，泰達工廠18783.6平方米，建筑面積合計13644.13平米，凈化廠房總計9202平方米。企業年均銷售額3億左右，擁有世界先進的生產設備、檢測儀器和先進的生產工藝的企業。優秀的產品品質和經營誠信在市場樹立了良好的品牌形象和產品知名度。企業共有固定員工800人左右，由一支優秀的忠于企業的管理隊伍和一支誠實、忠厚、吃苦耐勞的職工隊伍組成，是一個和諧、快樂、極富競爭力的團隊。企業股份變更后，新的領導團隊加大管理力度，引入OA、ERP、5S、合理化建議、精細化管理等新型管理模式，管理效率得到進一步改善。
企業以科技為未來發展戰略，積極承擔科技項目，提升自身科技水平，先后獲得天津市企業技術中心、天津市企業重點實驗室認定。企業重大改進產品“新型血液凈化裝置體外循環血液管路（血液回路）”獲得“天津市殺手锏產品”和“天津市專精特新產品”認定，該產品已形成一定規模的經濟效益，且產品銷售覆蓋全國二十多個省市，出口日本的產品達到8600萬元，在日本血液回路市場占有率30%。企業新產品“多功能輸液器”獲得“天津市重點新產品”認定，該產品在企業主打輸液器產品的基礎上設計開發，迎合臨床使用要求，具有革命性意義。未來企業將逐漸向內銷轉化，進一步降低銷售成本，為國內市場提供更高標準的醫療耗材產品，創造更大市場價值。
新產品“多功能輸液器”獲得“天津市重點新產品”認定，此外企業還承擔市科委科技支撐重點項目、科技小巨人了領軍企業培育項目、濱海新區科技小巨人項目等多項科技項目。擁有有效專利44項，其中發明專利5項，實用新型專利20項，外觀設計專利14項，另有專利申請十余件。
企業秉承“做全球品牌的醫用管路專業生產基地，做大做強國內市場，適機拓展國際市場”的戰略。未來企業將通過廠房擴建，破除向行業高端化發展的瓶徑，達到集中生產、節省管理和人工成本的目的，為全面向自動化智能化生產轉型打好基礎。企業下一步計劃研發新產品包括：血栓切除術系統、山諾士®隨行寶消毒噴劑、胰島素針、靜脈治療類等高附加值項目。隨著企業自身產能的大幅度提高，未來將減少對外加工式生產模式的依賴，特別是隨著具有國內獨家知識產權的血栓切除術系統、山諾士®隨行寶消毒噴劑等一批新品的投產和上市，企業在行業高端市場的競爭力也將得到進一步增強。我們有充分地理由相信，在未來的5年內，依靠本企業自身的品牌、技術、質量的優勢，完全有能力占領全國醫用高分子材料高端市場的半壁江山。
盡管近年來公司不斷地在品牌影響力與渠道建立上加大投資力度，但仍存在產品線不夠豐富、產能以及配套人員和生產設備一定程度上不能滿足市場需求等問題。因此近年來企業一直實行自主生產為主，外加工生產為輔的策略，有七家外加工廠配合公司進行產品的生產。為了節約成本，實現統一管理，更好地控制產品質量，開發更豐富的高附加值產品，為市場和患者提供更高標準的一次性使用醫療器械，哈娜好將擴建廠房，不僅將外加工廠業務收回改為自主生產，提高公司生產效率；并且緊跟行業發展趨勢，為公司生產血栓切除術系統、胰島素針、靜脈治療類等高附加值產品提供生產空間和條件，為公司全面向自動化、智能化生產轉型打好基礎。
新廠房包括研發中心、實驗室、辦公用房及生活配套用房；生產區包括凈化車間、原料庫、產成品倉庫、危險品庫、動力用房等，總建筑面積約為58150平方米。購置生產設備866臺、實驗儀器設備40臺、公用工程系統及環保設施設備14臺。項目達產后，各產品生產規模為：血液回路3500 萬套，安全采血針8000 萬套，采血針、頭皮針120 萬套，導管、導絲100 萬條，麻醉針1200 萬套，血管血栓去除平臺12 萬套，山諾士®隨行保消毒120 萬套，胰島素針5000 萬套，留置針4000 萬套，中心靜脈導管60 萬套。
TianJin Hanaco Medical Co.,Ltd, established in1986, is one pioneer of Sino foreign joint ventures of producing disposable medical high polymer product.The company carried on the updated change of equity in April.2019 and is wholly owned by TianJin TianShiZe investment & management center. With occupation of 143,677.63 square meters space。
The Insistence for quality control over years accumulates perfect reputation for the enterprise and make it keep good market shares and competitive strength. So far, TianJin Hanaco Medical Co.,Ltd has been the member of Tianjin Medical Device Industry Association and Tianjin International communication Association, the member of the Standard Committee on Infusion set and of the high polymer industry association and of Tianjin Biomedical Engineering Society, the enterprise of national high-technology and the leading and cultivated small giant enterprise of Tianjin science and technology.
The series of products produced with the brand of“HANACO”or“哈娜好”including disposable infusion sets,disposable sterile hypodermic syringe,disposable blood transfusion sets,disposable scalp vein sets, disposable dialysis bloodlines, disposable Arterial Venous fistula sets,disposable angiographic catheter and disposable blood collection sets and so on, reached up to the international standard and got approval of ISO13485&CE。In the initial stage of promoting GMP, the company got the first approval as the trial enterprise, and experienced and passed through many FDA plant audits.The scope of product covers all China and North and South America,Europe and Asia. Hanaco has nearly a dozen of offices and dozens of distributors in TianJin, BeiJing, ShangHai, ShenYang, HaErBin, WuHan, XiAn, HangZhou and NanJing, and the product is exported to nearly 20 countries like US, Japan, Korea, Saudi Arabia, Philippine, Srilanka and countries in South Africa.
TianJin Hanaco Medical Co.,Ltd has occupation space of 40,010.3 square meters in TianYi factory and 18,783.6 square meters in TEDA factory and 9202 square meters for purified workshop.The total structural area of production and development base project which has got the approval to be in construction stage in Airport economic zone is 84,883.63 square meters and the total structural area of purified workshop is 50,300 square meter. The annual sales amount of enterprise is around RMB300,000,000 and we are the enterprise with global advanced production equipment, inspection apparatus and up-to-date production arts and crafts. Excellent quality and business sincerity establish very good brand image and reputation of product. The enterprise with 800 permanent employeesconsisting of an outstanding and faithful management team and an honest, sincere and hard-working worker team is a harmonized, happy and very competitive team. After the change of equity, the new teamleaders of enterprise engage in strengthening the management, introducing updated management mode like OA、ERP、5S、rational proposal、fine management and further improving the management efficiency.
Regarding technology as future development strategy, actively undertaking science and technology project and promoting its scientific and technological level, the enterprise successively got the approval from Tianjin Enterprise Technology Center, Tianjin Enterprise Key Laboratory. The product“new blood purified device -- bloodline set”on critical changes by the enterprise obtained the approval from “Tianjin master-card product” & “Tianjin specialized and new product”. The product has formed a certain scale of economic benefits, and been sold over 20 provinces and cities in China, the sales amount reaches up to RMB86,000,000 on Japan direction and the product takes 30% market shares in Japan bloodline market. The new product“multifunctional infusion set” which obtained the approval from“Tianjin key & new product” is designed and explored on the base of focus on IV set to meet clinical-use requirement and to be revolutionary significance.The enterprise will gradually shift the sales focus to the domestic to reduce the cost of sales, to provide disposable medical product with higher standard for the domestic market and to create greater market value.
The new product“multifunctional infusion set”obtained the approval from“Tianjin key & new product” and the enterprise which undertook many scientific and technological projects like the key project supported by Municipal Science and Technology Commission, and the project of little giant in TEDA owns 5 patents for invention and 20 patents for practical and new patent and 14 patents for exterior design of total 44 effective patents and about a dozen patent applications.
The enterprise is always following the strategy of “Being the professional production base for global medical blood tubing set, being bigger and stronger in China domestic market and seeking the chance to explore the global market”. The enterprise will get the goal of centralizing production and saving the cost of management and labor through plant expansion and break of bottleneck in the process of industrial advanced development, and lay the foundation for transformation toward total automatic and intelligent production. The new products to be planned for the next step are: thrombectomy system, Sanosil sustainable shield disinfectant spray, insulin needle, products for treatment by venous and some high added value projects. Relying on the mode of OEM process will be reduced in the future as the significant increase on the capacity of the enterprise itself and the competitiveness of enterprise in advanced market of this industry will be further enhanced especially as the production and going public of thrombectomy system, Sanosil sustainable shield disinfectant spray and some new products with exclusive domestic intellectual property rights. We’re in deep trust for that we totally have capability to conquer half of advanced market of medical high-polymer material in China.
To some extent, the problem of insufficient production line and the problem of lacking productivity, correspondent staff and production equipment are still hardly to meet market requirement although our company is always increasing investments on brand promotion and establishment of distribution channel. Therefore, the enterprise is always implementing the strategy of independent production as main and OEM production as supplementary in recent years, and 7 outsourcing plants for cooperation on production. In order to save the cost, to realize unified management, to be better to control the product quality, to develop more abundant and high added value product and to provide disposable medical equipment with higher standard for the market and patient, Hanaco selected industrial area of 76,000 square meters in Tianjin airport economic and developed zone in 2019 to construct the new production and development base(total area of structure 84,883.63 square meters). Hanaco not only retracted the business from outsourcing plants and returned into independent production for promoting productive efficiency and following the trend of industry development, but also supplied production space and condition for thrombectomy system, insulin needle,high added value products of venous treatment and laid on the foundation for the complete automatic and intelligent production transformation.
The new factory in total area of structure 58150 square meters includes research center, lab, office and living area; the working area includes purified workshop, raw material storehouse, storehouse for finished products, storage for dangerous goods and power room. We purchased production equipment 866pcs,inspection equipment 40pcs、public engineering system and environmental equipment 14pcs. When the production is ready, the production scale of these products is ： BL set 350,000pcs，safety blood collection needle 80,000,000pcs，blood collection needle and scalp vein sets 1,200,000pcs, guide wire and catheter 1,000,000pcs，spinal needle 12,000,000pcs，thrombectomy 120,000pcs，Sanosil sustainable shield disinfectant spray 1,200,000pcs，insulin needle 50,000,000pcs，IV catheter 40,000,000pcs，central venous catheter 600,000pcs.
